Shamburg News · 8-K filed Nov 13, 2026, 8:05 AM EST
PDS Biotechnology Reports Third Quarter 2026 Financial Results and Business Update
PDSB · PDS Biotechnology Corp
- Earnings
- Financing
- Leadership change
- Other event
- Materiality: high
PDS Biotechnology Corporation reported a net loss of $7.6 million, or $0.11 per basic and diluted share, for the quarter ended September 30, 2026, compared with $9.0 million, or $0.19 per share, a year earlier. Research and development expenses were $2.1 million and general and administrative expenses were $3.8 million for the quarter. The company reported cash and cash equivalents of $15.2 million as of September 30, 2026, and announced the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001140361-26-043542.
Written from the filing by Shamburg Markets. Figures are as reported by the company.